Luis O. Carreras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Luis O. Carreras has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Marta Martinuzzo
Department of Haematology, Thrombosis and Haemostasis, Favaloro University, and Institute of Cardiology and Cardiovascular Surgery, Favaloro Foundation, Buenos Aires, Argentina
2 shared publicationsBeatriz Alonso
From the Hospital of Infectious Diseases “F. J. Muñiz” and, Buenos Aires, Argentina
1 shared publicationCristina Falcón
Departamento de Fisiologia, Facultad de Medicina (M.D.Z., D.P.C., M.I.V.), and Sectión Hemostasia y Trombosis, División Hematologia, Hospital de Clinicas José de San Martin (M.M., C.F., L.O.C.), Uniuersidad de Buenos Aires Buenos Aires, Argentina
1 shared publicationDaniel P. Cardinali
Departamento de Fisiologia, Facultad de Medicina (M.D.Z., D.P.C., M.I.V.), and Sectión Hemostasia y Trombosis, División Hematologia, Hospital de Clinicas José de San Martin (M.M., C.F., L.O.C.), Uniuersidad de Buenos Aires Buenos Aires, Argentina
1 shared publicationG. Cerrato
From the Institute of Cardiology and Cardiovascular Surgery, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
1 shared publicationG. Pombo
From the Institute of Cardiology and Cardiovascular Surgery, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
1 shared publication
Latest Publications
- Open Access
- 1 September 2001
- Published by Wiley in British Journal of Haematology
- Vol. 114 (4) , 845-851
Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies
Recent studies have shown that patients with antiphospholipid antibodies (aPL) have increased lipid peroxidation. We evaluated the urinary excretion of 11‐dehydro thromboxane B2 (11‐DH‐TXB2) and isoprostane F2αIII (IPF2αIII), reflecting platelet activation and lipid peroxidation in vivo, and plasma soluble markers of endothelial cell, platelet and blood coagulation activation: soluble vascular cell adhesion molecule‐1 (sVCAM‐1), P‐ and E‐selectin (sPsel and sEsel), F1 + 2 fragment of prothrombin (F1 + 2), thrombin–antithrombin complexes (TAT) and D‐Dimer (DD). We studied 79 patients with aPL (47 with previous thrombosis), 45 healthy volunteers (normal controls, NC), 12 patients with systemic lupus erythematosus (SLE) without aPL and a thrombosis control group (TCG) without thrombophilia (n = 16). Urinary levels (mean, range) of eicosanoids and isoeicosanoids were significantly increased in 39 patients with aPL compared with 25 NC, 11‐DH‐TXB2 164·0 ng/mmol creatinine (9·5–1162·8) versus 43·4 ng/mmol creatinine (4·2–87·6), P < 0·001; IPF2αIII 56·9 pg/mg creatinine (5·5–388·7) versus 27·0 pg/mg creatinine (4·6–87·6), P = 0·03. Both metabolites were significantly correlated (ρ= 0·49, P = 0·014), but none correlated with any clinical manifestation or antibody profile. The aPL group presented increased levels of sPsel, sEsel, sVCAM‐1, TAT, F1 + 2 and DD, but any soluble marker correlated with IPF2αIII. Urinary 11‐DH‐TXB2 correlated with sPsel (ρ= 0·39, P = 0·04). Compared with SLE controls, the SLE group with aPL had higher levels of F1 + 2. Plasma levels of F1 + 2 and DD were significantly increased and a trend to higher sPsel was found in aPL patients with thrombosis compared with the TCG. Platelet activation, lipid peroxidation and blood coagulation activation seem to be important in the pathophysiology of antiphospholipid syndrome.
- 1 September 2001
- Published by Wiley in British Journal of Haematology
- Vol. 114 (4) , 845-851
Open AccessIncreased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies
Recent studies have shown that patients with antiphospholipid antibodies (aPL) have increased lipid peroxidation. We evaluated the urinary excretion of 11‐dehydro thromboxane B2 (11‐DH‐TXB2) and isoprostane F2αIII (IPF2αIII), reflecting platelet activation and lipid peroxidation in vivo, and plasma soluble markers of endothelial cell, platelet and blood coagulation activation: soluble vascular cell adhesion molecule‐1 (sVCAM‐1), P‐ and E‐selectin (sPsel and sEsel), F1 + 2 fragment of prothrombin (F1 + 2), thrombin–antithrombin complexes (TAT) and D‐Dimer (DD). We studied 79 patients with aPL (47 with previous thrombosis), 45 healthy volunteers (normal controls, NC), 12 patients with systemic lupus erythematosus (SLE) without aPL and a thrombosis control group (TCG) without thrombophilia (n = 16). Urinary levels (mean, range) of eicosanoids and isoeicosanoids were significantly increased in 39 patients with aPL compared with 25 NC, 11‐DH‐TXB2 164·0 ng/mmol creatinine (9·5–1162·8) versus 43·4 ng/mmol creatinine (4·2–87·6), P < 0·001; IPF2αIII 56·9 pg/mg creatinine (5·5–388·7) versus 27·0 pg/mg creatinine (4·6–87·6), P = 0·03. Both metabolites were significantly correlated (ρ= 0·49, P = 0·014), but none correlated with any clinical manifestation or antibody profile. The aPL group presented increased levels of sPsel, sEsel, sVCAM‐1, TAT, F1 + 2 and DD, but any soluble marker correlated with IPF2αIII. Urinary 11‐DH‐TXB2 correlated with sPsel (ρ= 0·39, P = 0·04). Compared with SLE controls, the SLE group with aPL had higher levels of F1 + 2. Plasma levels of F1 + 2 and DD were significantly increased and a trend to higher sPsel was found in aPL patients with thrombosis compared with the TCG. Platelet activation, lipid peroxidation and blood coagulation activation seem to be important in the pathophysiology of antiphospholipid syndrome.
- 1 January 2001
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 86 (09) , 934-935
Imbalance towards Th2-Type Response in Patients with Definite Primary Antiphospholipid Syndrome
- 1 January 2001
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 86 (09) , 934-935
Imbalance towards Th2-Type Response in Patients with Definite Primary Antiphospholipid Syndrome
- 1 September 2000
- Published by Elsevier in Journal of Autoimmunity
- Vol. 15 (2) , 163-172
Which are the Best Biological Markers of the Antiphospholipid Syndrome?
- 1 September 2000
- Published by Elsevier in Journal of Autoimmunity
- Vol. 15 (2) , 163-172
Which are the Best Biological Markers of the Antiphospholipid Syndrome?
- 1 January 2000
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 83 (03) , 509-510
Factor V Leiden and Prothrombin G 20210A Variant Are Risk Factors for Venous Thromboembolism in the Argentinean Population
- 1 January 2000
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 83 (03) , 509-510
Factor V Leiden and Prothrombin G 20210A Variant Are Risk Factors for Venous Thromboembolism in the Argentinean Population
- 24 December 1999
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 118 (3) , 480-486
Binding properties of antibodies to prothrombin and β2-glycoprotein I (β2-GPI) assayed by ELISA and dot blot
Most anti-phospholipid antibodies (aPL) associated with the anti-phospholipid syndrome are autoantibodies with specificity towards β2-GPI (anti-β2-GPI) or prothrombin (anti-II). They are mainly screened by ELISA using polyoxygenated plates. However, some authors have claimed that immunoblotting can also be used. Exposure of cryptic epitopes or increase of antigen density on its binding to either phospholipids or suitable plastic surfaces are the two hypotheses proposed for the interaction of β2-GPI or prothrombin with their antibodies. Forty-five patients with aPL were studied: 25 with lupus anti-coagulant (LA) and anti-cardiolipin antibodies (aCL), 10 with LA alone and 10 with aCL but negative LA. All patients with LA and aCL were positive for anti-β2-GPI by ELISA and dot blot, while 15/25 had anti-IIELISA and 14 of them also had anti-II by dot blot assay. No patient with LA alone tested positive for anti-β2-GPI by ELISA or dot blot, whereas 6/10 had anti-IIELISA (five of them were also positive by dot blot). Four out of 10 aCL-positive patients had anti-β2-GPI by ELISA and dot blot, while none of this group had anti-II by ELISA or dot blot. Antibody binding to β2-GPI or prothrombin in both ELISA and dot blot was significantly reduced by phospholipid liposomes mixed together with β2-GPI or prothrombin, whereas liposomal eluants retained it in both assays. Parallel fluid-phase inhibition experiments using increasing concentrations (up to 200 μg/ml) of β2-GPI or prothrombin demonstrated that antibody binding reduction was more evident on dot blot than on ELISA. It was almost completely abolished on dot blot, while on ELISA a moderate inhibition was achieved even at the highest protein concentration. However, antibody binding on ELISA was virtually abolished when diluted sera were incubated with high protein concentrations applied to nitrocellulose membranes. We could infer that ELISA and dot blot detect antibodies with some differences in avidity but directed against native epitopes on β2-GPI and prothrombin.
- 24 December 1999
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 118 (3) , 480-486
Binding properties of antibodies to prothrombin and β2-glycoprotein I (β2-GPI) assayed by ELISA and dot blot
Most anti-phospholipid antibodies (aPL) associated with the anti-phospholipid syndrome are autoantibodies with specificity towards β2-GPI (anti-β2-GPI) or prothrombin (anti-II). They are mainly screened by ELISA using polyoxygenated plates. However, some authors have claimed that immunoblotting can also be used. Exposure of cryptic epitopes or increase of antigen density on its binding to either phospholipids or suitable plastic surfaces are the two hypotheses proposed for the interaction of β2-GPI or prothrombin with their antibodies. Forty-five patients with aPL were studied: 25 with lupus anti-coagulant (LA) and anti-cardiolipin antibodies (aCL), 10 with LA alone and 10 with aCL but negative LA. All patients with LA and aCL were positive for anti-β2-GPI by ELISA and dot blot, while 15/25 had anti-IIELISA and 14 of them also had anti-II by dot blot assay. No patient with LA alone tested positive for anti-β2-GPI by ELISA or dot blot, whereas 6/10 had anti-IIELISA (five of them were also positive by dot blot). Four out of 10 aCL-positive patients had anti-β2-GPI by ELISA and dot blot, while none of this group had anti-II by ELISA or dot blot. Antibody binding to β2-GPI or prothrombin in both ELISA and dot blot was significantly reduced by phospholipid liposomes mixed together with β2-GPI or prothrombin, whereas liposomal eluants retained it in both assays. Parallel fluid-phase inhibition experiments using increasing concentrations (up to 200 μg/ml) of β2-GPI or prothrombin demonstrated that antibody binding reduction was more evident on dot blot than on ELISA. It was almost completely abolished on dot blot, while on ELISA a moderate inhibition was achieved even at the highest protein concentration. However, antibody binding on ELISA was virtually abolished when diluted sera were incubated with high protein concentrations applied to nitrocellulose membranes. We could infer that ELISA and dot blot detect antibodies with some differences in avidity but directed against native epitopes on β2-GPI and prothrombin.
- 1 January 1999
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 81 (02) , 317-318
Acquired Hypoprothrombinemia Related to High Titres of Antiprotein-phospholipid Antibodies
- 1 January 1999
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 81 (02) , 317-318
Acquired Hypoprothrombinemia Related to High Titres of Antiprotein-phospholipid Antibodies
- 1 January 1990
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 70 (1) , 246-251
Inhibition of Human Platelet Aggregation and Thromboxane-B2Production by Melatonin: Evidence for a Diurnal Variation*
The effects of melatonin on platelet aggregation and thromboxane-B2 (TxB2) production induced by 1–4 × 10−−6m adenosine diphosphate (ADP) or 0.6 × 10−3m arachidonic acid (AA) were assessed in platelet-rich plasma (PRP). Micromolar concentrations of melatonin inhibited in a dose-dependent way ADP-induced platelet aggregation with individual inhibitions 40% or more at 10−6−10−5m. A significant depression of AA-induced platelet aggregation was observed only at 10−5−10−4m melatonin. Morning (0830 h)-evening (1800 h) studies of ADP-induced platelet aggregation in seven normal men showed a higher sensitivity at 1800 h when analyzed as a global inhibitory effect of melatonin (P < 0.01). Moreover, only during the evening hours did melatonin induce reversible aggregation, an index of inhibition of the platelet secretory process elicited by ADP exposure. No diurnal variability in melatonin inhibition of AA-induced aggregation was detected. TxB2 production elicited by AA in the evening was inhibited significantly in a concentration-related manner by a 2-min preincubation with 10−9−10−5m melatonin, while during the morning hours the inhibition was significant only at 10−6m or higher melatonin concentrations. In the case of ADP, the inhibition of TxB2 release attained significance at 10−5-m (0830 h) or 10−6-m concentrations (1800 h). In the presence of either stimulatory agent, melatonin depression of TxB2 generation was about 2-fold greater at 1800 h than at 0830 h. The diurnal changes in melatonin effect on TxB2 production were also observed in thrombin-stimulated washed platelets. The present data indicate the existence of circadian variations in platelet responsiveness to melatonin in humans.
- 1 January 1990
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 70 (1) , 246-251
Inhibition of Human Platelet Aggregation and Thromboxane-B2Production by Melatonin: Evidence for a Diurnal Variation*
The effects of melatonin on platelet aggregation and thromboxane-B2 (TxB2) production induced by 1–4 × 10−−6m adenosine diphosphate (ADP) or 0.6 × 10−3m arachidonic acid (AA) were assessed in platelet-rich plasma (PRP). Micromolar concentrations of melatonin inhibited in a dose-dependent way ADP-induced platelet aggregation with individual inhibitions 40% or more at 10−6−10−5m. A significant depression of AA-induced platelet aggregation was observed only at 10−5−10−4m melatonin. Morning (0830 h)-evening (1800 h) studies of ADP-induced platelet aggregation in seven normal men showed a higher sensitivity at 1800 h when analyzed as a global inhibitory effect of melatonin (P < 0.01). Moreover, only during the evening hours did melatonin induce reversible aggregation, an index of inhibition of the platelet secretory process elicited by ADP exposure. No diurnal variability in melatonin inhibition of AA-induced aggregation was detected. TxB2 production elicited by AA in the evening was inhibited significantly in a concentration-related manner by a 2-min preincubation with 10−9−10−5m melatonin, while during the morning hours the inhibition was significant only at 10−6m or higher melatonin concentrations. In the case of ADP, the inhibition of TxB2 release attained significance at 10−5-m (0830 h) or 10−6-m concentrations (1800 h). In the presence of either stimulatory agent, melatonin depression of TxB2 generation was about 2-fold greater at 1800 h than at 0830 h. The diurnal changes in melatonin effect on TxB2 production were also observed in thrombin-stimulated washed platelets. The present data indicate the existence of circadian variations in platelet responsiveness to melatonin in humans.